
Angenta0.5 mg+10
Healthcare Pharmaceuticals Ltd.
Established Use Flupentixol + Melitracen is used for the symptomatic treatment of mild-to-moderate depressive and anxiety states, particularly conditions with mixed anxiety-depressive features and more.
Flupentixol + Melitracen is used for the symptomatic treatment of mild-to-moderate depressive and anxiety states, particularly conditions with mixed anxiety-depressive features, including psychogenic depression, depressive neurosis, masked depression, and asthenia (marked lack of energy and motivation). Flupentixol + Melitracen is also used for psychosomatic conditions accompanied by anxiety and for menopausal-related depressive symptoms.
Flupentixol + Melitracen has also been used as an adjunct for dysphoria and low mood occurring in patients recovering from alcohol or other substance use disorders, under specialist supervision.
Flupentixol + Melitracen is not a treatment for severe major depression, psychotic depression, or schizophrenia as a primary agent, and it is not recommended for excitable, agitated, or overactive patients (see Contraindications). It is not indicated for use in children or adolescents.
Dosing of Flupentixol + Melitracen is individualized based on the severity of symptoms and the patient's age, and treatment is generally initiated at the lowest effective dose. See the table below for typical adult and elderly regimens.
| Population / Situation | Typical Regimen of Flupentixol + Melitracen |
|---|---|
| Adults (usual dose) | One tablet in the morning and one tablet at noon (a total of two tablets daily) |
| Adults (more severe symptoms) | The morning dose may be increased to two tablets, in addition to the usual noon tablet, under physician guidance |
| Maintenance / mild symptoms | One tablet in the morning may be sufficient once symptoms have improved |
| Elderly patients (over 65 years) | One tablet in the morning; maintenance is typically one tablet daily |
| Children and adolescents | Not recommended; safety and efficacy have not been established (see Pediatric Uses) |
| Hepatic impairment | Flupentixol + Melitracen is contraindicated in severe hepatic impairment; use with caution and reduced dose in milder impairment (see Use in Special Populations) |
Flupentixol + Melitracen should generally not be continued for more than a few months without medical reassessment, and any previous sedative tranquilizer should be withdrawn gradually rather than stopped abruptly when starting Flupentixol + Melitracen (see Precautions and Warnings).
Flupentixol + Melitracen is contraindicated in patients with:
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.